Pyrotinib (SHR-1258): A Comprehensive Pharmacological and Clinical Monograph

Executive Summary

Pyrotinib is an orally bioavailable, small-molecule targeted therapy developed by Jiangsu Hengrui Medicine that has emerged as a potent and clinically significant agent in the management of Human Epidermal Growth Factor Receptor 2 (HER2)-positive cancers.[1] Identified by the internal code SHR-1258 and marketed in China under the brand name Irene, Pyrotinib functions as an irreversible, pan-ErbB receptor tyrosine kinase inhibitor (TKI).[4] Its primary mechanism of action involves the covalent and sustained inhibition of Epidermal Growth Factor Receptor (EGFR/HER1), HER2, and HER4, thereby blocking critical downstream oncogenic signaling pathways, including the PI3K/Akt and RAS/RAF/MAPK cascades, which are fundamental drivers of tumor cell proliferation and survival.[5]

The clinical development of Pyrotinib has been marked by a series of successful pivotal trials, primarily in the field of HER2-positive breast cancer. The Phase III PHOEBE trial established its superiority in the second-line metastatic setting, demonstrating statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS) when combined with capecitabine, compared to the established TKI lapatinib with capecitabine.[8] In the first-line metastatic setting, the Phase III PHILA trial showed that the addition of Pyrotinib to a regimen of trastuzumab and docetaxel resulted in a profound extension of PFS versus the control arm, validating a powerful dual anti-HER2 blockade strategy.[11] Furthermore, promising data from neoadjuvant and extended adjuvant studies suggest its utility across the entire continuum of HER2-positive breast cancer care.[3]

The safety profile of Pyrotinib is considered manageable but is characterized by a high incidence of specific adverse events directly linked to its mechanism of action. Diarrhea is the most common and dose-limiting toxicity, frequently reaching grade 3 severity and requiring proactive management with antidiarrheal agents and potential dose modifications.[16] Other notable adverse events include hand-foot syndrome, nausea, and myelosuppression.[16]

Pyrotinib has achieved conditional and full marketing approval from the China National Medical Products Administration (NMPA) for multiple indications in HER2-positive breast cancer, solidifying its role as a standard of care within China.[19] As of the latest available data, it has not received approval from the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), though global clinical trials are underway.[21] Pyrotinib represents a significant therapeutic advance, offering a highly effective oral TKI that has redefined treatment paradigms for HER2-positive malignancies in the regions where it is approved and signals a new era of global oncology drug development.

Drug Profile and Chemical Characteristics

A precise understanding of a drug's identity and its chemical and physical properties is fundamental to its research, development, and clinical application. This section details the nomenclature, chemical structure, and physicochemical characteristics of Pyrotinib.

Identification and Nomenclature

Pyrotinib is the established generic name for this small molecule drug.[24] It is widely known in scientific literature and clinical trials by its developmental identifier, SHR-1258.[1] The drug has been assigned the DrugBank Accession Number DB14993 and is uniquely identified by the Chemical Abstracts Service (CAS) Number 1269662-73-8 for its free base form.[1] The commercially available form is often a maleate salt, which has a distinct CAS Number of 1397922-61-0.[25] Additional synonyms used in various contexts include Irene (its brand name in China), BLTN, and Pyrroltinib maleate.[4]

The development of Pyrotinib was led by Jiangsu Hengrui Medicine Co., Ltd. (also referred to as Shanghai Hengrui Pharmaceutical), a prominent biopharmaceutical company headquartered in China.[2] The extensive clinical development program has involved collaborations with major academic institutions, including the Chinese Academy of Medical Sciences and Peking Union Medical College Hospital.[4]

Chemical and Physicochemical Properties

Pyrotinib is a synthetic small molecule belonging to the 4-aminoquinoline class of organic compounds.[24] Its chemical structure is complex, incorporating several functional groups, including an acrylate, an amide, a quinoline ring system, an aminophenyl ether, and a chlorobenzene moiety, which contribute to its specific binding and pharmacological activity.[24]

The IUPAC (International Union of Pure and Applied Chemistry) name for Pyrotinib is (R,E)-N-(4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide.[1] Its chemical formula is

C32​H31​ClN6​O3​, corresponding to an average molecular weight of 583.09 g/mol and a monoisotopic mass of 582.2146166 g/mol for the free base.[24] The structure can be uniquely represented by its SMILES (Simplified Molecular Input Line Entry System) code: O=C(NC1=C(OCC)C=C2N=CC(C#N)=C(NC3=CC=C(OCC4=NC=CC=C4)C(Cl)=C3)C2=C1)/C=C/[C@@H]5N(C)CCC5.[1]

Physically, Pyrotinib is an off-white to white solid formulated for oral administration.[1] Its solubility profile is a key characteristic; it is soluble in organic solvents like dimethyl sulfoxide (DMSO) but is considered insoluble in water.[25] This property influences its formulation and absorption characteristics. For laboratory and long-term storage, it is recommended that the compound be kept in a dry, dark environment at -20°C, with short-term storage permissible at 0-4°C.[1]

The table below consolidates the key identification and physicochemical properties of Pyrotinib.

Table 1: Drug Identification and Physicochemical Properties of Pyrotinib

Parameter	Value/Description	Source(s)
Generic Name	Pyrotinib	24
Synonyms	SHR-1258, Irene, BLTN, Pyrotinib maleate	1
Developer	Jiangsu Hengrui Medicine Co., Ltd.	2
DrugBank ID	DB14993	24
CAS Number (free base)	1269662-73-8	1
CAS Number (maleate)	1397922-61-0	25
Chemical Formula (free base)	C32​H31​ClN6​O3​	1
Molecular Weight (free base)	Average: 583.09 g/mol; Monoisotopic: 582.21 g/mol	24
IUPAC Name	(R,E)-N-(4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide	1
Chemical Class	4-aminoquinoline derivative; pan-ErbB Tyrosine Kinase Inhibitor	24
Solubility	Soluble in DMSO; Insoluble in water	25
Appearance	Off-white to white solid	1
Storage Conditions	Dry, dark; -20°C (long term), 0-4°C (short term)	1

Mechanism of Action and Cellular Pharmacology

The clinical efficacy of Pyrotinib is rooted in its precise and potent molecular mechanism. As a second-generation tyrosine kinase inhibitor, its design incorporates features that confer distinct advantages in targeting the oncogenic signaling driven by the ErbB family of receptors.

Target Profile and Binding Kinetics

Pyrotinib is a pan-ErbB receptor tyrosine kinase inhibitor, meaning it broadly targets multiple members of the human epidermal growth factor receptor (HER) family.[6] Its primary targets are EGFR (also known as HER1 or ErbB1), HER2 (ErbB2), and HER4 (ErbB4).[5] It demonstrates high potency against these receptors, with reported half-maximal inhibitory concentrations (

IC50​) in the low nanomolar range: 13 nM for EGFR and 38 nM for HER2 in one analysis, and 5.6 nM for HER1 and 8.1 nM for HER2 in another.[5] This potent activity is highly selective; its inhibitory effect on other kinases, such as KDR, c-Kit, and PDGFRβ, is substantially weaker, with

IC50​ values typically over 3000 nM.[29]

A defining feature of Pyrotinib's mechanism is its irreversible mode of inhibition. Unlike first-generation, reversible TKIs such as lapatinib, Pyrotinib forms a permanent, covalent bond within the ATP-binding pocket of its target receptors.[5] This bond is formed with specific cysteine residues (e.g., Cys-773 in EGFR, Cys-805 in HER2) located in the intracellular kinase domain.[5] By occupying the ATP-binding site permanently, Pyrotinib prevents the binding of adenosine triphosphate (ATP), which is essential for kinase activity. This action effectively and irreversibly blocks receptor autophosphorylation, the critical first step in signal transduction.[5]

This irreversible binding provides a significant pharmacological advantage. While reversible inhibitors require sustained plasma concentrations to effectively compete with intracellular ATP, Pyrotinib's inhibitory effect persists long after the drug has been cleared from the plasma. The targeted kinase remains inactivated until the cell synthesizes a new receptor protein. This sustained and comprehensive target blockade is believed to be a primary driver of Pyrotinib's robust clinical efficacy, particularly its demonstrated superiority over the reversible inhibitor lapatinib in head-to-head clinical trials.[8]

Inhibition of Downstream Signaling Pathways

The ErbB receptor family is a central node in signaling networks that control cell growth, survival, and differentiation. In many cancers, particularly HER2-positive breast cancer, these pathways are pathologically overactive.[5] The activation sequence begins when ligand binding (or constitutive activation in the case of HER2 overexpression) promotes the formation of receptor dimers—either homodimers (e.g., HER2-HER2) or heterodimers (e.g., HER2-HER3).[5] HER2 is the preferred dimerization partner for all other ErbB receptors, and HER2-containing heterodimers are exceptionally potent signal transducers.[5] This dimerization brings the intracellular kinase domains into close proximity, leading to their autophosphorylation and the initiation of downstream signaling cascades.

By irreversibly preventing this initial phosphorylation event, Pyrotinib effectively shuts down the two principal oncogenic pathways that are aberrantly activated in HER2-driven cancers [5]:

1. The PI3K/Akt/mTOR Pathway: This is a critical pro-survival pathway. Its activation promotes cell growth and proliferation while actively suppressing apoptosis (programmed cell death). Its blockade by Pyrotinib is a key component of the drug's antitumor effect.[5]
2. The RAS/RAF/MEK/MAPK Pathway: This pathway is a primary regulator of cell proliferation, differentiation, and migration. Its inhibition directly curtails the uncontrolled growth characteristic of cancer cells.[5]

The pan-ErbB inhibitory profile of Pyrotinib may offer an additional layer of efficacy. Cancer cells can develop resistance to therapies targeting a single receptor by creating "escape routes" through the upregulation of other family members. For instance, a tumor might adapt to a HER2-specific inhibitor by increasing its reliance on EGFR signaling. By simultaneously inhibiting EGFR, HER2, and HER4, Pyrotinib may preemptively close off these potential resistance pathways, leading to more durable responses. However, this broad activity is also directly linked to its characteristic side effect profile. Potent EGFR inhibition is a well-known cause of dermatologic and gastrointestinal toxicities, and the high rate of diarrhea observed with Pyrotinib is a direct clinical manifestation of its potent, on-target EGFR blockade.

Cellular and Antineoplastic Effects

The molecular actions of Pyrotinib translate into potent and specific antineoplastic effects at the cellular level. In vitro studies have confirmed its target-specific activity, showing high potency against HER2-overexpressing cancer cell lines like BT474 (IC50​ = 5.1 nM) and SK-OV-3 (IC50​ = 43 nM), with markedly weaker effects on HER2-negative cell lines.[29] The ultimate cellular consequences of inhibiting the PI3K/Akt and MAPK pathways include cell cycle arrest, primarily at the G1/S transition phase, a profound inhibition of tumor cell proliferation, and the induction of apoptosis.[5]

These cellular effects have been validated in preclinical in vivo models. In mouse xenograft models using human breast (BT474) and ovarian (SK-OV-3) cancer cells, oral administration of Pyrotinib led to robust, dose-dependent tumor growth inhibition and, in some cases, complete tumor regression.[29] The overall antineoplastic activity observed in patients—the inhibition of tumor growth, suppression of angiogenesis (the formation of new blood vessels to feed the tumor), and regression of established tumors—is a direct result of this potent and sustained blockade of ErbB family signaling.[25]

Pharmacokinetic Profile

The pharmacokinetic (PK) profile of a drug describes its absorption, distribution, metabolism, and excretion (ADME), which collectively determine its concentration at the site of action over time. The PK properties of Pyrotinib are crucial for establishing its optimal dosing regimen and for understanding potential drug interactions and variability among patients.

Absorption

Pyrotinib is formulated for oral administration, with the recommended clinical dose being 400 mg taken once daily.[18] A critical aspect of its absorption is a significant food effect; administration with a meal increases its bioavailability, and the dosing instructions specify taking it after a meal to ensure consistent and optimal exposure.[30]

The absorption process is relatively slow, with the time to reach maximum plasma concentration (Tmax​) typically occurring between 3 to 5 hours after a dose.[30] Within the therapeutic dose range of 80 mg to 400 mg, Pyrotinib exhibits linear pharmacokinetics, meaning that the maximum concentration (

Cmax​) and the total drug exposure over time (Area Under the Curve, AUC) increase proportionally with the dose.[32] Upon repeated daily dosing, steady-state plasma concentrations are achieved within approximately 8 days, and clinical studies have shown no evidence of major drug accumulation over time.[32]

Distribution

Once absorbed into the bloodstream, Pyrotinib distributes widely throughout the body. This is evidenced by its large apparent volume of distribution (Vd​/F), which is estimated to be around 3820 to 4000 L.[30] This large value suggests extensive distribution into tissues outside of the plasma.

Pyrotinib is highly bound to plasma proteins, with a binding rate of approximately 95%.[30] In vitro data further specify that a substantial portion of this binding (58.3%) is covalent, a direct consequence of its irreversible mechanism of action where the drug forms a permanent bond with proteins like albumin.[32] Population PK analyses have identified patient age and total serum protein levels as factors that can influence the volume of distribution, but the magnitude of this effect was not considered clinically significant enough to necessitate dose adjustments based on these covariates.[32]

Metabolism

Metabolism is the primary pathway for the clearance of Pyrotinib from the body.[30] The drug is extensively metabolized by the hepatic cytochrome P450 (CYP) enzyme system. Specifically, the CYP3A4 isoform is the predominant enzyme responsible, accounting for an estimated 90% of Pyrotinib's metabolic clearance.[30] This heavy reliance on a single metabolic pathway makes Pyrotinib susceptible to drug-drug interactions with potent modulators (inhibitors or inducers) of CYP3A4.

Excretion

Following metabolism, the byproducts of Pyrotinib are eliminated from the body primarily through the feces, which accounts for over 90% of its excretion.[19] A mass balance study using a radiolabeled version of the drug confirmed that approximately 92.6% of the administered dose is recovered in excretions.[30] Only a very small fraction of the unchanged parent drug is eliminated, with about 12% found in the feces of fasted subjects and a negligible amount (~0.13%) in the urine.[30] Biliary excretion of the parent drug is considered a minor contributor to its overall clearance.[30]

The table below provides a summary of the key pharmacokinetic parameters for Pyrotinib.

Table 2: Summary of Key Pharmacokinetic Parameters of Pyrotinib

PK Parameter	Value/Description	Source(s)
Recommended Dose	400 mg orally, once daily	18
Food Effect	Bioavailability is significantly increased with food; should be taken after a meal.	30
Time to Max. Concentration (Tmax​)	3–5 hours	30
Apparent Volume of Distribution (Vd​/F)	~3820–4000 L	30
Plasma Protein Binding	~95% (with a significant covalent component)	30
Primary Metabolism	Hepatic; ~90% via Cytochrome P450 3A4 (CYP3A4)	30
Primary Excretion Route	Feces (>90%)	19
Drug Accumulation	No major accumulation observed with repeated daily dosing	32
Known Drug Interactions	- Capecitabine: No significant PK interaction. - Montmorillonite Powder: Reduces Pyrotinib bioavailability by ~50%. - CYP3A4 Modulators: Strong potential for interaction.	30

The pharmacokinetic profile reveals a critical triad of clinical considerations. First, adherence to taking the drug with food is essential for achieving therapeutic exposure. Second, the drug's primary toxicity is severe diarrhea. Third, a common over-the-counter treatment for diarrhea, montmorillonite powder, drastically reduces the drug's absorption by over 50%.[19] This creates a scenario where a patient experiencing the drug's main side effect might inadvertently render their cancer therapy sub-therapeutic by taking the wrong supportive medication. This highlights an exceptional need for meticulous patient education regarding not only how to take Pyrotinib but also how to correctly manage its primary side effect to ensure both safety and efficacy are maintained.

Clinical Efficacy in HER2-Positive Malignancies

The clinical development program for Pyrotinib has systematically established its efficacy across various settings of HER2-positive breast cancer and is exploring its utility in other HER2-driven malignancies. The evidence is built upon a foundation of large, randomized Phase III trials that have demonstrated statistically significant and clinically meaningful benefits.

Metastatic Breast Cancer (MBC) – Second-Line and Beyond

Pyrotinib's initial approvals and strongest evidence base are in patients with HER2-positive MBC who have progressed on prior therapies.

The PHOEBE Trial (Phase III)

The pivotal PHOEBE trial (NCT03709422) was a randomized, open-label, Phase III study that cemented Pyrotinib's role in the second-line or later treatment setting. The trial compared the efficacy and safety of Pyrotinib plus capecitabine versus lapatinib plus capecitabine in 267 patients with HER2-positive MBC whose disease had progressed after treatment with trastuzumab and taxane-based chemotherapy.[8]

The results were unequivocally in favor of Pyrotinib. The study met its primary endpoint of progression-free survival (PFS), with the Pyrotinib arm demonstrating a median PFS of 12.5 months compared to 6.8 months in the lapatinib arm (Hazard Ratio 0.39; p<0.0001).[8] This represented a 61% reduction in the risk of disease progression or death. With extended follow-up, Pyrotinib also demonstrated a significant overall survival (OS) benefit. The latest analysis, with a median follow-up of approximately 50 months, reported a median OS of 39.4 months for the Pyrotinib group versus 28.6 months for the lapatinib group, corresponding to a 22% reduction in the risk of death.[10] The Pyrotinib combination also yielded a higher objective response rate (ORR) of 67.2% compared to 51.5% for the lapatinib arm.[37] The PHOEBE trial's demonstration of superiority over an existing standard-of-care TKI was instrumental in establishing Pyrotinib as a preferred treatment option in this patient population in China.[9]

The PHENIX Trial (Phase III)

Prior to the PHOEBE results, the Phase III PHENIX trial provided placebo-controlled evidence for the Pyrotinib-capecitabine combination. In this study, patients were randomized to receive Pyrotinib plus capecitabine or placebo plus capecitabine.[16] The trial confirmed the potent activity of the combination, showing a median PFS of 11.1 months in the Pyrotinib arm versus just 4.1 months in the placebo arm (HR 0.18; p<0.001).[16] A key feature of this trial was the crossover design, which allowed patients in the placebo group to receive Pyrotinib monotherapy upon disease progression. In this crossover cohort, Pyrotinib alone demonstrated substantial antitumor activity, with an ORR of 38% and a median PFS of 5.5 months, validating its efficacy as a single agent.[16]

Real-World Evidence

Numerous observational and real-world studies conducted in China have corroborated the findings from these pivotal trials. These studies report consistent efficacy in heavily pre-treated populations, with median PFS values typically ranging from 8 to 14 months, and confirm that outcomes are generally better when Pyrotinib is used in earlier lines of therapy.[6]

Metastatic Breast Cancer (MBC) – First-Line Treatment

Building on its success in later-line settings, Pyrotinib was evaluated as a first-line therapy in the PHILA trial.

The PHILA Trial (Phase III)

The PHILA trial (NCT03863223) was a large, randomized, double-blind, placebo-controlled Phase III study involving 590 patients with previously untreated HER2-positive MBC.[12] The study was designed to assess the benefit of adding Pyrotinib to a standard dual-targeting backbone, comparing

Pyrotinib plus trastuzumab and docetaxel (PyroHT) to placebo plus trastuzumab and docetaxel (HT).

The trial met its primary endpoint with impressive results. The initial analysis showed that the PyroHT regimen more than doubled the median PFS, achieving 24.3 months compared to 10.4 months in the control arm (HR 0.41; p<0.001).[12] A subsequent final analysis confirmed this durable benefit, with a median PFS of 22.1 months versus 10.5 months (HR 0.44; p<0.0001).[43] The addition of Pyrotinib also translated into an OS benefit, with a hazard ratio of 0.64 (p=0.0038), indicating a significant reduction in the risk of death.[43] The PHILA results position this Pyrotinib-containing regimen as a highly effective new first-line option for HER2-positive MBC, providing an alternative to other dual anti-HER2 blockade strategies.[11]

Early-Stage Breast Cancer (Neoadjuvant and Adjuvant Settings)

The potent activity of Pyrotinib in the metastatic setting has prompted its investigation in early-stage breast cancer, where the goal is curative.

Neoadjuvant Therapy

In the neoadjuvant setting (treatment before surgery), Pyrotinib has shown remarkable efficacy. A Phase II trial that incorporated Pyrotinib into a standard chemotherapy and trastuzumab regimen (P + EC-TH) for patients with operable or locally advanced breast cancer reported a total pathological complete response (tpCR) rate of 73.7%.[14] A high tpCR rate is a strong surrogate marker for improved long-term outcomes. Based on these and other positive results, an NDA was filed in China for Pyrotinib in the neoadjuvant setting.[3]

Extended Adjuvant Therapy

In the adjuvant setting (treatment after surgery to prevent recurrence), the Phase II PERSIST trial evaluated one year of Pyrotinib as "extended" adjuvant therapy for high-risk patients who had already completed a standard year of trastuzumab-based treatment.[15] The trial reported a promising 2-year invasive disease-free survival (iDFS) rate of 94.59%, suggesting that Pyrotinib could serve a role similar to that of neratinib in this setting, aiming to further reduce the risk of late recurrence.[15]

This comprehensive development program, with positive data from first-line metastatic to neoadjuvant settings, reflects a strategic effort to establish Pyrotinib as a foundational TKI across the entire spectrum of HER2-positive breast cancer treatment.

Special Populations and Emerging Indications

Pyrotinib's efficacy is also being explored in challenging patient populations and other HER2-driven cancers.

Brain and Liver Metastases

As a small molecule, Pyrotinib has the potential to cross the blood-brain barrier and treat central nervous system (CNS) metastases, a common and difficult-to-treat site of progression in HER2-positive breast cancer. Multiple studies, including the dedicated PERMEATE trial, have shown that Pyrotinib-based regimens are active in patients with brain metastases, yielding median PFS times in the range of 7 to 11 months.[6] Studies have also confirmed its efficacy in patients with liver metastases, although these patients tend to have a poorer prognosis compared to those without liver involvement.[46]

Other Solid Tumors

The application of Pyrotinib is expanding beyond breast cancer to other tumors where HER2 is a driver mutation. It has shown promising clinical benefits in patients with non-small cell lung cancer (NSCLC) harboring HER2 exon 20 mutations, and the global Phase III PYRAMID-1 trial is currently comparing Pyrotinib to docetaxel in this population.[3] Additionally, clinical trials are actively recruiting patients with other HER2-positive solid tumors, including Esophageal Squamous Cell Carcinoma (ESCC) and Biliary Tract Cancer.[48]

The tables below summarize the key efficacy and safety outcomes from the pivotal PHOEBE and PHILA trials.

Table 3: Efficacy and Safety Outcomes from the Phase III PHOEBE Trial

Endpoint	Pyrotinib + Capecitabine	Lapatinib + Capecitabine	Hazard Ratio (95% CI)	p-value
Median PFS	12.5 months	6.8 months	0.39 (0.27–0.56)	<0.0001
Median OS	39.4 months	28.6 months	0.78 (0.61–0.99)	-
ORR	67.2%	51.5%	-	0.0091
Grade ≥3 Diarrhea	25.4%	7.6%	-	-
Grade ≥3 Hand-Foot Syndrome	14.9%	15.2%	-	-
	8

Table 4: Efficacy and Safety Outcomes from the Phase III PHILA Trial

Endpoint	Pyrotinib + Trastuzumab + Docetaxel	Placebo + Trastuzumab + Docetaxel	Hazard Ratio (95% CI)	p-value
Median PFS (Final Analysis)	22.1 months	10.5 months	0.44 (0.36–0.53)	<0.0001
Median OS (Updated Analysis)	Not Reached	Not Reached	0.64 (0.46–0.89)	0.0038
Grade ≥3 Diarrhea	25.6%	1.0%	-	-
Grade ≥3 Neutropenia	61.3%	55.6%	-	-
	12

The consistent success of Pyrotinib in combination with the extracellular anti-HER2 antibody trastuzumab in trials like PHILA and neoadjuvant studies highlights a powerful therapeutic principle. This "dual blockade" strategy targets the HER2 receptor from both outside the cell (with the antibody) and inside the cell (with the TKI). This provides a more comprehensive and synergistic shutdown of the HER2 signaling pathway than either agent could achieve alone, offering a strong mechanistic rationale for the potent efficacy observed in these combination regimens.[44]

Safety, Tolerability, and Management of Adverse Events

While Pyrotinib has demonstrated impressive efficacy, its clinical use is defined by a distinct and predictable safety profile. Understanding these adverse events (AEs) and their management is critical for optimizing patient outcomes and maintaining treatment adherence.

Overview of the Safety Profile

Pyrotinib-based therapy is associated with a high frequency of treatment-related adverse events, with some studies reporting that over 90% of patients experience at least one AE.[52] However, the majority of these events are low-grade and considered manageable with supportive care and dose modifications.[7] Importantly, in major clinical trials, severe AEs leading to death have been reported as rare or absent, indicating that while toxicities are common, they are generally not life-threatening when managed appropriately.[10]

Common and Severe Adverse Events

The AE profile of Pyrotinib is directly related to its pan-ErbB mechanism of action, with toxicities reflecting the inhibition of EGFR, HER2, and HER4.

• Diarrhea: This is the hallmark toxicity of Pyrotinib. It is the most frequently reported AE and the most common reason for dose reduction or interruption. The incidence of any-grade diarrhea is consistently high across studies, often affecting 73% to 98% of patients.[18] Grade 3 or 4 (severe or life-threatening) diarrhea is also the most common severe AE, with reported rates ranging from approximately 15% to 31% in key trials, making it the primary dose-limiting toxicity.[5]
• Hand-Foot Syndrome (HFS): Also known as palmar-plantar erythrodysesthesia, HFS is another very common AE, characterized by redness, swelling, and pain on the palms of the hands and soles of the feet. Its incidence is particularly high in regimens that combine Pyrotinib with capecitabine, a chemotherapy agent also known to cause HFS.[16] Grade 3/4 HFS has been reported in 16% to 25% of patients in these combination studies.[16]
• Myelosuppression: Inhibition of bone marrow function is a common class effect of many anticancer agents. With Pyrotinib, this typically manifests as:
• Neutropenia/Leukopenia: A decrease in white blood cells, particularly neutrophils, is frequently observed. The rate of severe (Grade 3/4) neutropenia is highly dependent on the combination regimen. While relatively modest with capecitabine (~9%) [17], it is much higher (>60%) when combined with myelosuppressive chemotherapy like docetaxel.[12]
• Anemia: A decrease in red blood cells is also common, with Grade 3 anemia reported in up to 14% of patients in some studies.[53]
• Other Common Adverse Events: A range of other AEs are frequently reported, including nausea, vomiting, fatigue (asthenia), decreased appetite, and oral mucositis (mouth sores).[7]

Management of Adverse Events

Effective management of Pyrotinib's side effects is paramount to enabling patients to stay on this effective therapy. The primary strategies involve supportive care and dose modification.

• Dose Modifications: The standard 400 mg daily dose of Pyrotinib can be reduced in a stepwise fashion to 320 mg and then to 240 mg per day to manage intolerable toxicities.[14] Temporary treatment interruption for up to two weeks is also a valid strategy to allow for recovery from acute AEs.[16]
• Management of Diarrhea: Given its high incidence and potential severity, diarrhea requires a proactive and aggressive management approach. Patients should be educated on the risk and instructed to begin treatment at the first sign of loose stools. The recommended antidiarrheal agent is loperamide, which can be used for both prevention in high-risk scenarios and for active treatment.[54] As previously noted in the pharmacokinetic section, it is crucial to avoid the use of montmorillonite powder, as it can significantly impair the absorption and efficacy of Pyrotinib.[19]

Contraindications and Precautions

While no absolute contraindications are listed, exclusion criteria from pivotal clinical trials provide a strong indication of patient populations in whom Pyrotinib should be used with caution or avoided. These include patients with pre-existing significant cardiac disease (e.g., congestive heart failure, LVEF <50%), as HER2 signaling plays a role in cardiac function.[55] Patients must also have adequate baseline organ function, including normal hematologic, hepatic, and renal parameters, before initiating therapy.[16] The drug is contraindicated in pregnancy and lactation.[42]

The table below summarizes the most common and severe adverse events associated with Pyrotinib-based regimens.

Table 5: Summary of Common and Severe Adverse Events Associated with Pyrotinib-Based Regimens

Adverse Event	Any Grade Incidence (%)	Grade 3-4 Incidence (%)	Key Management Notes
Diarrhea	73–98%	15–31%	Most common DLT. Proactive management with loperamide is critical. Avoid montmorillonite. Dose reduction/interruption for severe cases.
Hand-Foot Syndrome	27–79%	16–25%	Incidence is highest with capecitabine. Management includes moisturizers, avoiding friction, and dose modification.
Nausea/Vomiting	32–46%	<5%	Standard antiemetic therapy as needed.
Neutropenia/Leukopenia	Variable	9–61%	Incidence is highly dependent on the chemotherapy partner. Monitor blood counts regularly. Use of growth factors may be required.
Anemia	Variable	~14%	Monitor hemoglobin. Transfusions may be required for severe cases.
Fatigue	~37%	<5%	Patient education and energy conservation strategies.
Oral Mucositis	~29%	<5%	Good oral hygiene. Symptomatic relief with topical agents.
	5

Comparative Analysis with Other HER2-Targeted TKIs

The therapeutic landscape for HER2-positive breast cancer includes several oral tyrosine kinase inhibitors. Contextualizing Pyrotinib requires a direct comparison with its main predecessors and mechanistic relatives: lapatinib and neratinib.

Pyrotinib vs. Lapatinib

Lapatinib was the first small-molecule TKI approved for HER2-positive breast cancer and serves as a key benchmark. The comparison between Pyrotinib and lapatinib is particularly robust, as it is supported by direct, head-to-head Phase III clinical trial data.

• Mechanism: The most fundamental difference lies in their binding kinetics. Pyrotinib is an irreversible inhibitor that forms a permanent covalent bond with its targets, while lapatinib is a reversible inhibitor that engages in competitive binding with ATP.[5] This means Pyrotinib provides a more sustained and complete blockade of kinase activity. Furthermore, Pyrotinib has a broader target profile, inhibiting HER1, HER2, and HER4, whereas lapatinib's activity is primarily focused on HER1 and HER2.[5]
• Efficacy: The clinical consequence of these mechanistic differences was demonstrated unequivocally in the Phase III PHOEBE trial. In this head-to-head comparison in patients with pre-treated HER2-positive MBC, the combination of Pyrotinib and capecitabine was statistically superior to lapatinib and capecitabine across all major efficacy endpoints, including a significantly longer median PFS (12.5 vs. 6.8 months) and median OS (39.4 vs. 28.6 months).[8]
• Safety: The superior efficacy of Pyrotinib comes with a distinct safety trade-off. While both drugs cause diarrhea, the incidence and severity are notably higher with Pyrotinib. In a randomized Phase II trial, Grade 3/4 diarrhea occurred in 15.4% of patients in the Pyrotinib arm versus only 4.8% in the lapatinib arm.[17]
• Conclusion: Pyrotinib has proven to be a more potent and clinically effective TKI than lapatinib in the metastatic setting. It has superseded lapatinib as a standard of care in regions where it is available, though its use requires more vigilant management of gastrointestinal toxicity.

Pyrotinib vs. Neratinib

Neratinib is a more relevant mechanistic comparator to Pyrotinib, as they share key molecular features. However, no head-to-head clinical trials have been conducted, so comparisons must be made indirectly based on their individual datasets and established clinical roles.

• Mechanism: Pyrotinib and neratinib are mechanistic "cousins." Both are irreversible, pan-ErbB tyrosine kinase inhibitors that form covalent bonds with and inhibit EGFR (HER1), HER2, and HER4.[5] Their molecular mode of action is virtually identical.
• Efficacy: Both drugs have demonstrated significant clinical activity, but their development programs have emphasized different clinical settings.
• Metastatic Setting: Pyrotinib has a very strong evidence base in metastatic disease from the PHOEBE and PHILA trials, establishing it as a highly effective agent in both second-line and first-line therapy.[9] Neratinib has also shown activity in metastatic disease, but its pivotal trials in this space have yielded more modest results compared to Pyrotinib's.[5]
• Adjuvant Setting: Here, the roles are reversed. Neratinib is the established agent, with Level 1 evidence from the large, randomized, placebo-controlled ExteNET trial supporting its use as one year of extended adjuvant therapy to reduce the risk of recurrence.[5] Pyrotinib has shown promising data in this setting from the single-arm Phase II PERSIST trial, but this does not yet constitute the same level of evidence as ExteNET.[15]
• Safety: Their safety profiles are remarkably similar, a direct reflection of their shared mechanism. For both Pyrotinib and neratinib, diarrhea is the most common and most severe adverse event, representing the primary clinical challenge for both drugs.[5]
• Conclusion: Pyrotinib and neratinib are similar drugs that have been successfully developed for different primary roles in the HER2-positive breast cancer treatment algorithm. Pyrotinib is more established in treating active metastatic disease, while neratinib is the established standard for extended adjuvant therapy.

The table below provides a side-by-side comparison of these three key HER2-targeted TKIs.

Table 6: Comparative Profile of HER2-Targeted TKIs: Pyrotinib, Lapatinib, and Neratinib

Feature	Pyrotinib	Lapatinib	Neratinib
Mechanism of Binding	Irreversible (covalent)	Reversible (competitive)	Irreversible (covalent)
Primary Targets	EGFR (HER1), HER2, HER4	EGFR (HER1), HER2	EGFR (HER1), HER2, HER4
Key Efficacy Data (Metastatic)	Superior to lapatinib in head-to-head Phase III trial (PHOEBE); Potent first-line activity (PHILA)	Inferior to pyrotinib in head-to-head trial; Active vs. chemotherapy	Active, but pivotal trials have shown more modest benefit than pyrotinib
Key Efficacy Data (Adjuvant)	Promising Phase II data (PERSIST)	Not a standard adjuvant therapy	Approved for extended adjuvant therapy based on Phase III ExteNET trial
Most Common Severe AE	Diarrhea (Grade 3/4: ~15-31%)	Diarrhea (Grade 3/4: ~5-13%), Rash	Diarrhea (Grade 3/4: ~40%)
Regulatory Status	Approved in China	Approved in US/EU/China	Approved in US/EU/China
	5

Regulatory Status and Future Directions

The development and approval of Pyrotinib mark a significant milestone in oncology, reflecting both its clinical value and evolving trends in global pharmaceutical research and development. Its journey from a domestically developed compound to a standard of care in China, along with its ongoing investigation worldwide, provides a roadmap for its future.

Global Regulatory Landscape

The regulatory story of Pyrotinib is a prime example of a "China-first" development model, a departure from the traditional path where drugs are first approved by Western agencies.

• China (NMPA): Pyrotinib's first global approval was a conditional authorization granted by the China National Medical Products Administration (NMPA) in August 2018.[19] This initial approval was for its use in combination with capecitabine for patients with HER2-positive, advanced or metastatic breast cancer who had been previously treated with anthracyclines or taxanes, and was based on compelling Phase II data.[20] Following the successful outcomes of the Phase III PHOEBE and PHILA trials, Pyrotinib has received full approvals and expanded indications in China, establishing it as a standard of care for both second-line and first-line metastatic disease.[9] An NDA has also been accepted for its use in the neoadjuvant setting, signaling a further expansion of its approved applications.[3]
• United States (FDA) and Europe (EMA): As of the latest available information, Pyrotinib has not been granted marketing authorization by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).[22] It remains an investigational drug in these regions. However, the initiation of clinical trials in the U.S. (such as NCT02500199) and the global nature of studies like the PYRAMID-1 trial for NSCLC indicate a clear strategy for eventual regulatory submissions and global expansion.[3]

This development trajectory highlights the maturation of China's biopharmaceutical industry, which is now capable of taking a novel compound from discovery through large-scale pivotal trials to domestic regulatory approval, positioning its innovations on the global stage.

Resistance Mechanisms

As with all targeted therapies, acquired resistance is an inevitable clinical challenge. While Pyrotinib is effective in patients with primary or acquired resistance to trastuzumab, tumors can eventually develop resistance to Pyrotinib itself.[6] Research into these mechanisms is ongoing. One key area of investigation is the role of bypass signaling pathways. Hyperactivation of the PI3K/Akt pathway, often through mutations in genes like

PIK3CA, is a well-known mechanism of resistance to HER2-targeted therapies.[63] Indeed, one preclinical study showed that in a breast cancer model harboring a

PIK3CA mutation, the synergistic effect of Pyrotinib and trastuzumab was lost, suggesting that an intact, HER2-dependent signaling cascade is necessary for maximal benefit and that PI3K pathway activation is a likely route of primary resistance.[44] Future research will likely focus on identifying specific acquired mutations in

HER2 or other signaling molecules that confer resistance and on developing strategies to overcome it.

Future Directions and Ongoing Research

The research and development for Pyrotinib is dynamic and moving beyond its established indications into novel combinations and new disease settings. This signals a shift from proving its fundamental efficacy to optimizing its use and expanding its reach.

• Novel Combination Therapies: The next frontier for Pyrotinib lies in rational, biologically-driven combinations.
• With CDK4/6 Inhibitors: For hormone receptor-positive, HER2-positive breast cancer, combining Pyrotinib with a CDK4/6 inhibitor like dalpiciclib has shown promising activity in the Phase II PLEASURABLE trial, offering a potential chemotherapy-free regimen.[33]
• With Antibody-Drug Conjugates (ADCs): A highly anticipated area of research is the combination of Pyrotinib with next-generation ADCs. A clinical trial is underway to evaluate the safety and efficacy of Pyrotinib combined with trastuzumab deruxtecan (T-DXd), a pairing that could offer a profoundly potent antitumor effect by targeting HER2 via multiple, distinct mechanisms.[64]
• With Alternative Chemotherapies: The combination with oral vinorelbine is being investigated as an alternative to capecitabine, potentially offering a different safety profile.[6]
• Expansion into New Indications: Following the biological driver, trials are actively exploring Pyrotinib in any cancer type characterized by HER2 alterations. The most advanced of these is in non-small cell lung cancer (NSCLC) with HER2 mutations, with a global Phase III trial ongoing.[23] Early-phase trials are also recruiting patients with other HER2-positive solid tumors, such as esophageal and biliary tract cancers.[48]
• Optimizing Use in Breast Cancer: Research continues to refine Pyrotinib's role in breast cancer. This includes a trial comparing different formulations of trastuzumab (subcutaneous vs. intravenous) when combined with Pyrotinib to improve patient convenience [66], and large-scale, prospective real-world studies in China designed to gather further data on its long-term effectiveness and safety in routine clinical practice.[39]

In conclusion, Pyrotinib has firmly established itself as a cornerstone of HER2-targeted therapy in China and is poised for a broader global role. Its future development is focused on creating more effective and tolerable combination regimens, understanding and overcoming resistance, and extending its proven efficacy to a wider range of HER2-driven malignancies.

Works cited

1. Pyrotinib|CAS 1269662-73-8 - Sun-shine Chem, accessed August 4, 2025, https://www.sun-shinechem.com/Details/Pyrotinib/3979/1269662-73-8.html
2. Pyrotinib by Jiangsu Hengrui Medicine for Breast Cancer: Likelihood of Approval, accessed August 4, 2025, https://www.pharmaceutical-technology.com/data-insights/pyrotinib-jiangsu-hengrui-medicine-breast-cancer-likelihood-of-approval/
3. Jiangsu Hengrui Pharmaceuticals Co., Ltd., accessed August 4, 2025, https://www.hengrui.com/en/media/detail-60.html
4. Jiangsu Hengrui Medicine - Pyrotinib - AdisInsight - Springer, accessed August 4, 2025, https://adisinsight.springer.com/drugs/800038794
5. Mechanism, safety and efficacy of three tyrosine kinase inhibitors ..., accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6834479/
6. A retrospective real-world study of pyrotinib in HER-2 positive advanced breast cancer, accessed August 4, 2025, https://www.oncology-central.com/a-retrospective-real-world-study-of-pyrotinib-in-her-2-positive-advanced-breast-cancer/
7. What is the mechanism of Pyrotinib Maleate? - Patsnap Synapse, accessed August 4, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-pyrotinib-maleate
8. Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study - Frontiers, accessed August 4, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.699333/full
9. Pyrotinib Improves Survival in Previously Treated HER2-Positive Metastatic Breast Cancer, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8963278/
10. PHOEBE trial results show patients with advanced HER2-positive BC live longer on pyrotinib - ecancer, accessed August 4, 2025, https://ecancer.org/en/news/23888-phoebe-trial-results-show-patients-with-advanced-her2-positive-bc-live-longer-on-pyrotinib
11. ascopubs.org, accessed August 4, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.e13016#:~:text=Multiple%20studies%20have%20demonstrated%20the,HER2%2Dpositive%20advanced%20breast%20cancer.
12. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial | The BMJ, accessed August 4, 2025, https://www.bmj.com/content/383/bmj-2023-076065
13. A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer - larvol clin, accessed August 4, 2025, https://clin.larvol.com/trial-detail/NCT03863223
14. Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I–III HER2‐Positive Breast Cancer: A Phase II Clinical Trial, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8108050/
15. Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial - eLife, accessed August 4, 2025, https://elifesciences.org/reviewed-preprints/101724
16. Pyrotinib plus capecitabine for human epidermal factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study, accessed August 4, 2025, https://tbcr.amegroups.org/article/view/41552/html
17. Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study - ASCO Publications, accessed August 4, 2025, https://ascopubs.org/doi/abs/10.1200/JCO.19.00108
18. Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis - Frontiers, accessed August 4, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00811/full
19. A validated UPLC-MS/MS method for quantification of pyrotinib and population pharmacokinetic study of pyrotinib in HER2-positive breast cancer patients - PubMed Central, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11449865/
20. Pyrotinib: First Global Approval - ResearchGate, accessed August 4, 2025, https://www.researchgate.net/publication/328390891_Pyrotinib_First_Global_Approval
21. Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors - NCI, accessed August 4, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2017-00491
22. pyrotinib patents and clinical trials: Drug pipeline profiles for drugs in development, accessed August 4, 2025, https://www.drugpatentwatch.com/p/drugs-in-development/drugname/pyrotinib
23. Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy | ClinicalTrials.gov, accessed August 4, 2025, https://clinicaltrials.gov/study/NCT04447118
24. Pyrotinib: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 4, 2025, https://go.drugbank.com/drugs/DB14993
25. Pyrotinib free base | SHR-1258 | CAS# | 1397922-61-0 - MedKoo Biosciences, accessed August 4, 2025, https://www.medkoo.com/products/5777
26. Pyrotinib maleate | SHR-1258 | CAS# | 1397922-61-0 - MedKoo Biosciences, accessed August 4, 2025, https://www.medkoo.com/products/11697
27. Pyrotinib in the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: A case report - PMC, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7310977/
28. Definition of pyrotinib - NCI Drug Dictionary, accessed August 4, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pyrotinib
29. Pyrotinib (SHR-1258) | CAS NO.:1269662-73-8 | GlpBio, accessed August 4, 2025, https://www.glpbio.com/pyrotinib-shr-1258.html
30. Prediction of pyrotinib exposure based on physiologically ... - Frontiers, accessed August 4, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.972411/full
31. Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer - MDPI, accessed August 4, 2025, https://www.mdpi.com/2072-6694/11/6/737
32. Population pharmacokinetic modeling of pyrotinib in patients with HER2-positive advanced or metastatic breast cancer | medRxiv, accessed August 4, 2025, https://www.medrxiv.org/content/10.1101/2020.08.23.20179655.full
33. Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial | PLOS Medicine, accessed August 4, 2025, https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004669
34. Population pharmacokinetic modeling of pyrotinib in patients with HER2-positive advanced or metastatic breast cancer | medRxiv, accessed August 4, 2025, https://www.medrxiv.org/content/10.1101/2020.08.23.20179655v1
35. Abstract GS3-02: Updated overall survival (OS) results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2-positive metastatic breast cancer - AACR Journals, accessed August 4, 2025, https://aacrjournals.org/cancerres/article/82/4_Supplement/GS3-02/680227/Abstract-GS3-02-Updated-overall-survival-OS
36. Abstract GS3-02: Updated overall survival (OS) results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2-positive metastatic breast cancer - ResearchGate, accessed August 4, 2025, https://www.researchgate.net/publication/359103627_Abstract_GS3-02_Updated_overall_survival_OS_results_from_the_phase_3_PHOEBE_trial_of_pyrotinib_versus_lapatinib_in_combination_with_capecitabine_in_patients_with_HER2-positive_metastatic_breast_cancer
37. Effectiveness and safety of pyrotinib‐based therapy in patients with HER2‐positive metastatic breast cancer: A real‐world retrospective study - PubMed Central, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8633258/
38. Real-world efficacy and safety of pyrotinib in patients with ... - Frontiers, accessed August 4, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1100556/full
39. Pyrotinib in the first-line treatment of HER2-positive advanced breast cancer: Results from the PRETTY study. - ASCO Publications, accessed August 4, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.e13016
40. Pyrotinib shows promising efficacy and safety in HER+ advanced BC in the real-world, accessed August 4, 2025, https://blogs.the-hospitalist.org/content/pyrotinib-shows-promising-efficacy-and-safety-her-advanced-bc-real-world
41. Efficacy and Safety of Pyrotinib for Patients with HER2-Positive Advanced Breast Cancer: A Retrospective Multicenter Real-World Study - JScholar Publisher, accessed August 4, 2025, https://www.jscholaronline.org/articles/JCRTO/Efficacy-and-Safety-of-Pyrotinib-for-Patients-with-HER2-Positive.pdf
42. A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer | ClinicalTrials.gov, accessed August 4, 2025, https://clinicaltrials.gov/study/NCT03863223
43. Pyrotinib or placebo in combination with trastuzumab and docetaxel... - Xu B - GS1-03 - Dec 11 2024 - SABCS ePoster Gallery, accessed August 4, 2025, https://sabcs.multilearning.com/sabcs/2024/breast-cancer-symposium/4150499/binghe.xu.gs1-03.pyrotinib.or.placebo.in.combination.with.trastuzumab.and.html
44. Unraveling the synergistic mechanisms of pyrotinib in combination with trastuzumab: Insights from the PHILA trial. | Journal of Clinical Oncology - ASCO Publications, accessed August 4, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e13015
45. Efficacy and Safety of Pyrotinib in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Multicenter, Retrospective, Real-World Study - PubMed Central, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9527812/
46. Pyrotinib-Based Therapy May Improve Survival in Patients With HER2+ Breast Cancer and Liver Metastases - Pharmacy Times, accessed August 4, 2025, https://www.pharmacytimes.com/view/pyrotinib-based-therapy-may-improve-survival-in-patients-with-her2-breast-cancer-and-liver-metastases
47. Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer | ClinicalTrials.gov, accessed August 4, 2025, https://clinicaltrials.gov/study/NCT05751018
48. Pyrotinib Recruiting Phase 2 Trials for Esophageal Squamous Cell Carcinoma (ESCC) Treatment | DrugBank Online, accessed August 4, 2025, https://go.drugbank.com/drugs/DB14993/clinical_trials?conditions=DBCOND0106636&phase=2&purpose=treatment&status=recruiting
49. Study Details | A Trial of SHR1258 in Patients With Biliary Tract Cancer | ClinicalTrials.gov, accessed August 4, 2025, https://clinicaltrials.gov/study/NCT04571710
50. Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trial - PubMed, accessed August 4, 2025, https://pubmed.ncbi.nlm.nih.gov/39368454/
51. Retrospective Analysis of Pyrotinib-Based Therapy for Metastatic Breast Cancer: Promising Efficacy in Combination with Trastuzumab - PubMed Central, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11135571/
52. The efficacy and safety of pyrotinib in treating HER2-positive metastatic breast cancer patients: a multicentre study | Gao | Oncology in Clinical Practice - Via Medica Journals, accessed August 4, 2025, https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/105828
53. Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial - AACR Journals, accessed August 4, 2025, https://aacrjournals.org/clincancerres/article/25/17/5212/81637/Safety-Efficacy-and-Biomarker-Analysis-of
54. New treatment breakthrough: Pyrotinib combo demonstrates ..., accessed August 4, 2025, https://www.news-medical.net/news/20231102/New-treatment-breakthrough-Pyrotinib-combo-demonstrates-remarkable-efficacy-for-HER2-positive-metastatic-breast-cancer.aspx
55. The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study | ClinicalTrials.gov, accessed August 4, 2025, https://clinicaltrials.gov/study/NCT06770296
56. Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer | ClinicalTrials.gov, accessed August 4, 2025, https://clinicaltrials.gov/study/NCT01937689
57. (PDF) Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer - ResearchGate, accessed August 4, 2025, https://www.researchgate.net/publication/337260499_Mechanism_safety_and_efficacy_of_three_tyrosine_kinase_inhibitors_lapatinib_neratinib_and_pyrotinib_in_HER2-positive_breast_cancer
58. Pyrotinib: First Global Approval - PubMed, accessed August 4, 2025, https://pubmed.ncbi.nlm.nih.gov/30341682/
59. The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive | ClinicalTrials.gov, accessed August 4, 2025, https://clinicaltrials.gov/study/NCT06495541
60. Pyrotinib: a new promising targeted agent for human epidermal growth factor receptor 2-positive breast cancer, accessed August 4, 2025, https://tbcr.amegroups.org/article/view/41989/html
61. Jaypirca | European Medicines Agency (EMA), accessed August 4, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/jaypirca
62. Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors - PubMed Central, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11090794/
63. Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity - MDPI, accessed August 4, 2025, https://www.mdpi.com/2072-6694/13/7/1538
64. Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial | ClinicalTrials.gov, accessed August 4, 2025, https://clinicaltrials.gov/ct2/show/NCT06245824
65. Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+ Advanced Breast Cancer after Trastuzumab Failure (PROVE): A Prospective Phase 2 Study - PubMed Central, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12016823/
66. Study Details | Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer | ClinicalTrials.gov, accessed August 4, 2025, https://clinicaltrials.gov/study/NCT06537674